October 12, 2016. Healio Dermatology News. http://www.healio.com/dermatology/acne/news/online/%7B1c32b9dc-acd5-4e78-b072-6d9160e61127%7D/five-recent-developments-in-acne
Study findings that a family history of acne and various lifestyle factors were associated with adult acne in women was among recent developments in acne reported on Healio.com/Dermatology.
Other recent developments included research finding a combination of a superficial chemical peel, subcision and fractional CO2 laser resurfacing after tumescent anesthesia is a safe and effective treatment for rolling acne scars:
Lifestyle factors associated with adult female acne: A family history of acne and various lifestyle factors were associated with adult acne in women, according to recently published study results. Researchers measured factors associated with adult female acne in 248 women aged 25 years or older (mean age, 32.2 years) and 270 controls who were women (mean age, 36.4 years) diagnosed with conditions other than acne.
Single-session combination therapy successfully treats rolling acne scars: Researchers found that a combination of a superficial chemical peel, subcision and fractional CO2 laser resurfacing after tumescent anesthesia is a safe and effective treatment for rolling acne scars, according to a study data published in Dermatologic Surgery. Mark B. Taylor, MD, of Gateway Aesthetic Institute and Laser Center in Salt Lake City, and colleagues combined a trichloracetic acid 20% chemical peel and extensive subcision, using a novel instrument designed by Taylor, with fractional CO2 laser (Fraxel Re:Pair; Solta) to treat the rolling acne scars of 114 patients (75 women) with Fitzpatrick skin Types I-V.
BioPharmX announces BPX-01 reduces P. acnes by more than 90%: Final results of a phase 2A safety study of BPX-01 showed that the topical gel formulation of minocycline reduced facial P. acnes by 91% after 4 weeks, according to BioPharmX Corp. There was a significant reduction in P. acnes at 4 weeks in BPX-01 when compared with baseline as well as compared with the control cohort, according to a press release. There were no adverse cutaneous effects reported, and no minocycline detected in the plasma.
AOBiome trial to test live bacteria for acne treatment: AOBiome announced the launch recently of a phase 2b trial for its live topical bacterial therapy to treat acne in adults. Results from the company’s phase 1b/2a dose-ranging safety study showed no serious adverse events and no difference in adverse events between treatment and vehicle groups, according to a company press release.
Novan completes enrollment for phase 3 trials of SB204 gel: Novan completed enrollment for its two identically designed phase 3 clinical trials to evaluate the efficacy and safety of its topical nitric oxide-releasing product candidate SB204 gel for the treatment of acne, according to a press release. The NI-AC301 and NI-AC302 12-week parallel trials will each include approximately 1,300 patients aged 9 years and older who will be administered SB204 gel 4% topically once daily.